One of the hallmarks of Alzheimer's disease neurodegeneration is the accumulation of deposits of amyloid in neuritic plaques and in the cerebral vasculature.
Recent studies have implicated carboxy-terminal fragments of the Alzheimer amyloid precursor protein (BAPP) in the processes of amyloidogenesis and neurodegeneration.
In particular, the carboxy-terminal 104 amino acids of BAPP (@APP-C104) have been shown to cause amyloid-like fibrils when expressed in non-neuronal cells and to cause the degeneration of neuronal cells. These data suggest that it may play a role in the development of the progressive neuropathology of Alzheimer's disease. We hypothesized that @APP-Cl04 may cause the degeneration of neurons by interacting with a cell surface receptor.
In the present report, we show that /lAPP-Cl04 synthesized in vitro binds specifically and with high affinity to the surface of NGF-treated PC1 2 cells. Both the cell surface binding and the neurotoxicity of BAPP-Cl04 are pH dependent and are not inhibited by tachykinins. Mutational analysis suggests that both the binding and the neurotoxicity are dependent at least in part on the presence of a tyrosine residue that is a potential site of phosphorylation at the carboxy terminus of the fragment.
The deposition of amyloid in neuritic plaques and along the walls of the cerebral vasculature is a key feature of Alzheimer's disease pathology (Terry et al., 1981; Glenner, 1983) . The principal component of amyloid is a 4 kDa protein termed @IA4 (Glenner and Wong, 1984a,b; Masters et al., 1985) that is probably derived from one or more of four identified precursor proteins with predicted lengths of 695 (Kang et al., 1987) 751 (Ponte et al., 1988; Tanzi et al., 1988) 770 (Kitaguchi et al., 1988) and 714 amino acids (Golde et al., 1990) respectively. DNA sequence (Kang et al., 1987) and biochemical (Dyrks et al., 1988; Selkoe et al., 1988) studies suggest that the amyloid precursor protein (PAPP) is an integral membrane protein with the P/A4 peptide spanning the border between the extracellular domain and the transmembrane region. ,f3APP in cultured cells is rapidly processed from a membrane-bound form to a secreted form (Weidemann et al., 1989) ; pulse-chase studies show that the secretion of /3APP leaves behind a stable 11.5 kDa fragment consisting of the transmembrane region and the cytoplasmic domain (Oltersdorf et al., 1990) . This normal processing of @APP is a membrane-associated event that occurs within the extracellular domain of PIA4 (Esch et al., 1990; Sisodia et al., 1990) . Hence, the generation of ,&/A4 in Alzheimer's disease appears to be the result of abnormal cleavage. However, the molecular mechanisms of amyloidogenesis and the role of amyloidogenesis in the development of Alzheimer's disease pathology remain unclear.
Recent evidence has implicated the 100-104 amino acid carboxy-terminal fragment of @APP in the processes of amyloidogenesis and neurodegeneration. This fragment, which spans the @/A4 and cytoplasmic domains, has a tendency to self-aggregate (Dyrks et al., 1988) . Moreover, the expression of this carboxy-terminal pAPP fragment in primate cells has been shown to lead to the production of a 16 kDa protein that aggregates and accumulates into deposit-like structures (Wolf et al., 1990) and that results in the formation of amyloid-like fibrils (Maruyama et al., 1990) .
We have shown that this same carboxy-terminal @APP fragment is neurotoxic (Yankner et al., 1989) . PC12 cells transfected with a retroviral recombinant expressing the carboxy-terminal 104 amino acids of pAPP (formerly termed AB 1, Yankner et al., 1989 ; now termed PAPP-C104) degenerate when induced to differentiate into neuronal cells with NGF. Moreover, conditioned medium from these cells is toxic to differentiated neuroblastoma cells (Slave et al., 1989) and to neurons but not nonneuronal cells in primary rat hippocampal cultures (Yankner et al., 1989) . The neurotoxicity can be removed from the medium by immunoabsorption with an antibody to PAPP-Cl04 (Yankner et al., 1989) , suggesting that PAPP-Cl04 is secreted by the transfected cells and is neurotoxic. We have recently demonstrated that brain transplants of cells expressing PAPP-Cl04 cause specific neuropathology in vivo (Neve et al., in press) . We have also shown that transgenic mice expressing PAPP-Cl04 in the brain manifest intracellular and neuropil deposition of @IA4 protein, as well as other abnormalities that resemble aspects of Alzheimer's disease pathology (Kammesheidt et al., 199 1; and A. Kammesheidt and R. L. Neve, unpublished observations) . In B, the first lane shows fected RNA (neo in the case of the DO transfectants: BAPP-Cl04-neo reactivity ofantibody BX6 with @APP-ClO4, the second lane is a control fusion in the'case of the BAPP-Cl04 transfectants; see Yankner et al., with no primary antibody. 1989) .
To assay the toxicity of conditioned media from NIH 3T3 transfectants, the growth medium of the transfectants (DMEM plus 5% bovine calf serum; HyClone) was replaced with the PC 12 medium for 2 d when the 3T3 cell transfectants were at approximately 50% confluence. At the time that the conditioned media were harvested, RNA was isolated from the 3T3 cell transfectants and analyzed by Northern blots to confirm that all the transfectants were expressing equivalent amounts of mRNA from the appropriate transfected recombinant. PC1 2 cells were seeded at 1 O4 cells/well in polylysine-coated 24-well plates (Costar) and the conditioned media (diluted 1: 1 with PC1 2 medium) containina 50 @ml &NGF were applied and replaced every other day. To test-the ability of tachykinins to inhibit BAPP-Cl04 toxicity, each tachykinin analyzed was included in the conditioned medium at 20 PM, and replaced each time the conditioned medium was replaced.
The neurotoxicity of this carboxy-terminal /3APP fragment suggests that it may play a role not only in amyloidogenesis but also in the development of the progressive neuropathology of Alzheimer's disease. We have therefore sought to determine the mechanism by which PAPP-Cl04 causes the degeneration of neurons. We report here that PAPP-Cl04 synthesized in vitro binds specifically and with high affinity to the surface of NGFtreated PC12 cells. Both the cell surface binding and the neurotoxicity of/3APP-C 104 are pH dependent. Mutational analysis suggests that both the binding and the neurotoxicity are dependent at least in part on the presence of a tyrosine residue that is a potential site of phosphorylation at the carboxy terminus of the fragment.
Materials and Methods
Cell culture. PC1 2 cells for the binding assays were grown in RPM1 1640 (GIBCO) with the addition of 10% heat-inactivated horse serum (Hana Biological) and 5% fetal bovine serum (J.R. Scientific). T-175 'flasks (Falcon) were seeded with 5 x 10' cells/ml in 60 ml of growth medium containing 10 @ml NGF, An additional 60 ml of this medium were added every 2 d until the cells were harvested (usually at 6 d). Where indicated, PC12 cells were cultured as above except in the absence of NGF. Cells were collected bv centrifuaation at 138 x .e for 8 min. The supematant was discarded and the pellet resuspended in 5 ml of the growth medium. The cells were triturated three times through a 23 gauge needle attached to a 10 cc syringe to provide a single cell suspension or, at most, small cell aggregates. Trypan blue (Polyscience Inc.) dye exclusion indicated over 99% viable cells.
PC1 2 cells for the toxicity assays were grown in the presence of 10% CO, in Dulbecco's modified Eagle's medium (DMEM) (Sigma), 5% heatinactivated horse serum (HyClone), and 101 fetal bovine serum (HyClone) containing 50 @ml j3-NGF (gift of Dr. William Mobley). Cells were seeded at lo4 cells/well in polylysine-treated 24-well plates (Costar). The medium was replaced every 2 d. When the pH dependence of the toxicity was examined, a given pH was maintained by adding 25 mM HEPES to the medium and adjusting the medium to the desired pH at 36°C (the temperature at which the cells were maintained). The pH of the medium in the wells was rechecked during the course of the experiment. Four or more replicates of each experiment were plated, one field in each well containing 100-300 cells on day 0 was defined for cell counts. We returned to the same field for cell counts on subsequent days. Viability of the NGF-treated cells was determined on the basis of phase brightness of cell bodies, intactness of neurites (some cells became phase-dark due to spreading on the polylysine substrate but extended neurites in response to NGF, these cells were counted as viable as long as they had neurites), and adherence to substrate. All the Preparation andcharacterization of@APP-ClOlhnd 35S-fiAPP-C104. The B&I-SmaI franment of the BAPP-695 cDNA (bo 1769-2959 according to the sequence of Kang et al., 1987) , or of the appropriate mutant, was cloned into BamHI-SmaI-digested pGEM3 (Promega Biotee). The resulting recombinant was linearizied with ClaI (to make sense BAPP-Cl04 RNA using SP6 RNA polymerase) or Sal1 (to make antisense pAPP-Cl04 RNA using T7 RNA polymerase) and used as template to make 5'-capped RNA in vitro using Promega Biotec reagents and protocol. RNA (20 Irg) was typically synthesized in a 50 ~1 reaction using 5 fig of template. Two micrograms of this RNA were used in a 50 ~1 wheat germ lysate in vitro translation reaction together with 3.8 WCi of ?S-methionine (Amersham; 1200 Ci/mmol). The concentration of @APP-Cl04 in the lysates was determined by SDS-polyacrylamide gel electrophoresis of an aliquot of the in vitro translation product, followed by excision of the radiolabeled band from the dried and autoradiographed gel, solubilization of the band in H,O,, and quantitation of the radioactive protein in the band. The concentration of BAPP-C 104 in the band was extrapolated from these data, using the assumption that during the in vitro synthesis of 35S-@APP-C104, 35S-methionine was incorporated at all of the five methionine residue positions (specific activity, 11,000 Ci/mmol) in the polypeptide. The ?j-methionine was replaced with 80 PM methionine to make unlabeled BAPP-C104. A l/ 10 vol of 100 mM N-acetyl-D-glucosamine (Sigma) was added to each completed in vitro translation reaction to block the binding activity of wheat germ agglutinin before the reaction was aliquotted and stored at -80°C. The in vitro translation products were thawed only once for use in the binding assays. Multiple freeze-thaw cycles, which resulted in aggregation of in vitro translated BAPP-Cl04 (S. A. Fidel and R. L. Neve, unpublished observations), also resulted in loss of binding activity of the ?S-BAPP-C104. ?S-PAPP-Cl04 was 90% bindable to NGFtreated PC12 cells in conditions of binding site excess.
Receptor binding assay. For BAPP-C 104 binding experiments, PC1 2 cells, grown and prepared as described above, were counted, collected by low-speed centrifugation (138 x g), and resuspended in PBS (pH 7.4) with 1% BSA and 1% glucose (PBG). In the experiments in which the pH dependence of the binding was tested, pH values for the PBS ranged from 7.4 to 8.0. A 0.08 ml volume of the cell suspension, con- taining 2 x lo6 cells, was mixed with 0.01 ml of 35S-@APP-C104 and 0.01 ml of PBG, or PBG containing unlabeled ,f3APP-C104. For kinetic and inhibition experiments, the concentration of YS-BAPP-Cl04 was either 25 PM or 50 PM. For saturation experiments, the ligand concentration ranged from 15 PM to 6 nM. The mixture was incubated at 4°C for 3 hr, unless otherwise indicated. At the end of the incubation period, the cells were pelleted by centrifugation at 138 x g for 90 set, the supematant (containing the unbound ligand) was removed, and 0.2 ml of fresh, ice-cold PBG was added. The cells and fresh buffer were briefly agitated, and again centrifuged and suspended in fresh, ice-cold buffer as above. Final&, the cells were pelleted by centrifugation, filtered through BSA (I%)-treated filters using a Tomtec (Orange, CT) 96-well harvester, and washed with four 1 ml rinses of ice-cold PBS with 1% BSA. The duration of the period between resuspension of the cells in fresh, icecold buffer and filtration of the cells was less than 10 min. In the dissociation experiments and to collect a sample of bound ligand, the cells were incubated in the buffer added as the second wash for up to 3 hr to allow the bound ligand to dissociate. The cells were then pelleted by centrifugation and the supematant (containing the ligand that had dissociated) was removed. The cells were then rewashed and harvested as described above. Radioactivity retained by the filters was measured by scintillation counting using a Betaplate counter (LKB). Nonspecific binding was taken as that occurring in the presence of excess (3.2-18 nM) PAPP-ClO4. Saturation data were analyzed using LUNDON 1 binding analysis software (Lundeen and Gordon, 1986 ). The binding model that best fitted the experimental data was determined by F test (p < 0.05).
In vitro mutagenesis of @APP-004. In order to make mutants of PAPP-C104, we used oligonucleotide-directed in vitro mutagenesis as described by Kunkel(1985) . To change serine 603 to an alanine, a 20mer representing the reverse complement of bases 1795-l 8 14 (according to the sequence of Kang et al., 1987) that directs the alteration of the initial T of the serine codon to a G was used. To change tyrosine 687 to a phenylalanine, we constructed a 19mer representing the reverse complement of bases 2053-207 1 that directs the appropriate A to T alteration. The EcoRI-ClaI subfragment of @APP-C 104 was s&cloned into the phagescript vector SK M 13 (Stratagene) and introduced into the Escherichia coli dut, ung strain CJ236. The uracil-containing phage DNA produced in this strain was used as template in the in vitro mutagenesis reaction, which was transformed into E. coli MVll90 for selection against the parental strand. The mutated EcoRI-ClaI subfragment was used to replace the wild-type fragment in the DO recombinant, after which presence of the desired mutation was confirmed by sequence analysis.
Results

Synthesis and analysis of PAPP-Cl04
The portion of the /3APP cDNA encoding BAPP-Cl04 was cloned into the plasmid vector pGEM3, in which the cloning site is flanked by binding sites for SP6 and T7 RNA polymerases. The sense (or antisense control) transcript was synthesized and then (Fig. IA) .
To show that this band represented PAPP-C104, the in vitro translation extract was analyzed by immunoblot with an antibody (termed anti-BX6; Benowitz et al., 1989; Oltersdorfet al., 1990 ) directed against a bacterial fusion protein expressing PAPPCl04 (Fig. 1B) (Fig. 2) . The inhibitable fraction of the binding accounted for 40-60% of the total binding. The IC,, value for the inhibitable binding was 1.7 + 0.7 nM (n = 5). Inhibitable binding reached a maximum after 3 hr of incubation and was completely dissociable (Fig. 3) . (Table 1) . Non-sense 35S-labeled material synthesized from antisense PAPP-C 104 RNA did not bind to NGF-treated PC 12 cells. To assess the stability of 35S-PAPP-Cl04 in the assay conditions, samples of both free ligand at the end of the incubation (Fig. 5 ). This represents monomer BAPP-C104. A small amount of material was also present in two additional diffuse bands. One migrated at approximately twice the molecular weight of the major band and possibly represents a dimer of BAPP-C104. The other band had a much higher molecuiar weight and may be an aggregate. The gel profile of the unbound ligand at the end of the incubation period was identical to that of the ligand before incubation, indicating that the ligand had not been degraded. Similarly, the ligand released from binding had the same profile as the ligand originally added, with the possible exception of a slight reduction in the amount of high molecular weight material. These data show that the binding of PAPP-Cl04 ligand does not cause its modification.
Inhibition of binding of 35S-pAPP-C104 to NGF-treated PC12 cells by conditioned medium from @APP-Cl04-transfected PC12 cells Having identified a binding site for %-PAPP-Cl04 on the surface of NGF-treated PC 12 cells, we then carried out a series of experiments to ascertain whether the binding of PAPP-C 104 to these sites could account for its neurotoxicity. Because the degeneration caused by PAPP-C 104 occurs gradually over a period of 11 d, it was not feasible to synthesize the amount of in vitrotranslated ,f3APP-C 104 necessary to maintain a reasonable concentration of the peptide in the cultures for the full course of each experiment. Hence, we carried out, in parallel with the binding studies, cell culture studies utilizing PC12 cells stably transfected with a retroviral recombinant expressing pAPP-C 104 Dependence of both binding and neurotoxicity on exposure of cells to NGF We had previously reported (Yankner et al., 1989 ) that PC12 cells stably transfected with a retroviral recombinant expressing PAPP-Cl04 degenerate when caused to differentiate into neuronal cells with NGF. Thus, the neurotoxicity appears only after treatment of the cells with NGF. We therefore tested the effect of NGF on ,f3APP-Cl04 binding to PC1 2 cells, and found that the amount of inhibitable 35S-j3APP-C 104 binding was dependent upon the duration of exposure of the PC12 cells to NGF. PC12 cells that were not exposed to NGF showed little inhibitable binding, whereas those cultured in the presence of NGF for 4 or 6 d showed progressively greater amounts of binding (Fig. 6 ).
To confirm and extend our earlier results (Yankner et al., 1989) demonstrating the neurotoxicity of /?APP-Cl04 in culture, we evaluated the effects of NGF on PAPP-ClO'Ltransfected cells in serum-containing and serum-free medium. Two independently isolated PAPP-C 104 PC 12 cell transfectants (termed ABl-PC12 #l and #2 in Yankner et al., 1989 ) and a control vector-transfected PC 12 cell line (termed DO-PC 12 and described in Yankner et al., 1989) were treated with NGF in serum-containing medium (see Materials and Methods) or in serum-free medium (Ex-Cell30 1, JRH Biosciences), both at pH 7.3. The results, shown in Figure 7 , show that PAPP-C104-transfected PC 12 cells, but not DO-transfected PC 12 cells, gradually degenerate in the presence of NGF. The degeneration of the /3APP-C 104-transfected PC 12 cells was characterized by the appearance of vacuolar inclusions in the cell body, retraction of neurites, and loss of attachment of the cells to the substrate. In many cases (see Fig. 9B ), degenerating cells clumped together before floating into the medium; extensive fasciculation of processes was also evident among the remaining population of cells that did not show retraction of net&es.
Dependence of both binding and neurotoxicity on pH A second variable affecting binding was pH. A marked effect of pH on binding was observed between pH 7.7 and 7.9 (Fig. 8A) . Between pH 7.4 and 7.6, binding was relatively constant, or slightly declining. At approximately pH 7.7, there was a sharp increase in binding followed by a total loss at pH 7.8 to 7.9. Inhibitable binding was again seen at pH 8.0.
Because the 35S-PAPP-C104 binding to NGF-treated PC1 2 cells was pH dependent, we examined the pH dependence of NGF-induced degeneration of BAPP-C 104-transfected cells. Our initial studies of neurotoxicity in these cells had been carried with the medium at pH 7.3 (see above). We then compared the PAPP-Cl04 neurotoxicity in medium at pH 7.2 with that in medium at pH 8.2 (Fig. 9) . Because we had noted that cell loss was more rapid in serum-containing than in serum-free medium, we chose to carry out these and subsequent experiments in the presence of serum. PAPP-Cl04 transfectants displayed no detectable degeneration at pH 8.2 even after 9 d of treatment with NGF, whereas neurodegeneration of the transfectants was apparent by day 6 of NGF treatment at pH 7.2. Because HEPES was used to maintain the 8.2 pH, we included a HEPES control at pH 7.2 to show that HEPES alone is not sufficient to inhibit PAPP-C 104 neurotoxicity.
To examine in greater detail the pH dependence of PAPP-C 104 toxicity, we exposed control and experimental transfected PC1 2 cell lines to NGF in media at pH ranging from pH 7.2 (medium at pH lower than 7.2 was slightly toxic to control cells) to pH 8.2 in 0.1 pH unit increments (Fig. SB) . It is clear that the neurotoxicity of PAPP-Cl04 is dependent upon pH and is almost completely inhibited at pH 7.8 or above. Notably, binding of BAPP-C 104 to NGF-treated PC 12 cells is virtually lost at pH 7.8 and 7.9 (Fig. 8A) .
Lack of inhibition of @APP-Cl04 binding and neurotoxicity by tachykinins As stated above, binding of BAPP-C 104 to NGF-treated PC 12 cells was not significantly inhibited by a number of tachykinins (Table 1) . We tested the ability of the tachykinins listed in Table  1 (with the exception of neurokinin A) to inhibit @APP-Cl04 neurotoxicity. We had previously transfected NIH 3T3 cells with the same PAPP-C 104 retroviral recombinants and control vector that we used to transfect the PC 12 cells (Yankner et al., 1989) . We had shown that conditioned medium from the PAPP-C 104 transfected 3T3 cells, but not from the vector-transfected 3T3 cells, was toxic to NGF-differentiated PC12 cells. To examine the effect on ,&APP-C 104 neurotoxicity ofthe tachykinins, we added pAPP-C 104 NIH 3T3-conditioned medium containing NGF, or control conditioned medium containing NGF together with 20 PM of each tachykinin (as described in Yankner et al., 1990) , to PC1 2 cells. The cells exposed to PAPP-C104-conditioned medium, but not the cells exposed to control conditioned medium, degenerated over a period of 8 d; the degeneration was not inhibited by the presence of any of the tachykinins tested (n = 12 for each condition; data not shown). Mutational analysis of PAPP-Cl04 neurotoxicity and binding
By comparing the sequence of /3APP-Cl04 with that of other molecules with known functions, we identified at least two sites within @APP-C 104 that may play a role in its binding and neurotoxicity. The amino terminus of BAPP-Cl04 contains the ttipeptide aspartic acid-setine+lycine (residues 603-605 of @APP-695), which is conserved in the active site of serine proteases (Hartley, 1970) . Roberts (1986) has suggested that @/A4 or a similar @APP fragment may have serine protease activity and cause neurodegeneration by virtue of such activity. If @APP-Cl04 has serine protease activity, and if this activity is implicated in its neurotoxicity, it should be possible to neutralize its neurotoxicity by removing the serine residue in the putative serine protease active site. We used oligonucleotide-directed in vitro mutagenesis to change the serine at residue 604 (using the numbering system of Rang et al., 1987, for PAPP-695) to an alanine. The mutant was termed PAPP-Cl04 MutS. Two independent stable NIH 3T3 cell transfectants expressing this mutant mRNA at levels equivalent to or exceeding the PAPP-Cl04 mRNA levels in nonmutated transfectants were isolated and their conditioned media assayed for neurotoxicity by adding the media to NGF-treated PC 12 cells (see Materials and Methods). The conditioned media from the BAPP-Cl04 MutS 3T3 cells was as toxic to NGF-treated PC 12 cells as was the BAPP-C 104-conditioned medium (n = 8 for each condition; data not shown).
Thus, the replacement of serine 604 with an alanine in PAPPCl04 has no effect on its toxicity. The carboxy terminus of /3APP-C 104 contains a tyrosine (687 in PAPP-695) that lies within a sequence homologous to that surrounding a phosphorylated tyrosine in integrins and some plasma membrane receptors (reviewed by Tamkun et al., 1986) . This homology suggests that tyrosine 687 in BAPP-C 104 might be important to its function. We used site-directed mutagenesis to replace the tyrosine with a phenylalanine, and selected two stable NIH 3T3 cell transfectants (termed BAPP-Cl04 MutY) expressing the mutant mRNA at appropiate levels. The conditioned medium of these transfectants was not toxic to NGFtreated cells, although conditioned medium of a nonmutated PAPP-Cl04 3T3 cell transfectant tested at the same time was toxic to the NGF-treated cells (Fig. 10 ). In accordance with these data, @APP-C 104 MutY made in an in vitro transcription-translation system did not significantly inhibit ?S-PAPP-Cl04 binding to NGF-treated PC 12 cells at concentrations up to 14 nM (n = 3; Table l ), indicating that this mutant is at least 2.5 log units less potent in its binding affinity than is PAPP-C104.
Discussion
The present results show that the 35S-fiAPP-C104 binding site expressed by NGF-treated PC 12 cells has several receptorlike properties. First, it binds the ligand reversibly, as shown in the dissociation experiments. Second, it specifically recognizes the ligand in that binding is inhibited by unlabeled PAPP-Cl04 but not inhibited by other peptides, including tachykinins. Furthermore, a small modification of @APP-C 104 (the mutation of tyrosine 687) abolishes binding activity. Third, PAPP-Cl04 is not altered after binding as shown by SDS-PAGE analysis of the ligand, suggesting that the binding site is not an enzyme or, at least, not an enzyme that metabolizes BAPP-C 104 under these assay conditions. Finally, it has high (nanomolar) affinity and low capacity, as would be expected for a receptor.
Three of the present results provide circumstantial evidence that this binding site mediates the toxic effects of PAPP-Cl04 on differentiated PC12 cells. First, the binding site is much more prevalent on PC1 2 cells rendered susceptible to the toxic effects of PAPP-C 104 by treatment with NGF than on nontreated cells, to which the peptide is not toxic (Yankner et al., 1989) . The increase in PAPP-C 104 binding following NGF treatment is not due to the increased cell surface area that accompanies differentiation since, in the present study, the cells are not attached and therefore do not extend neurites. Second, a loss of both binding and toxicity occurs near pH 7.8. Third, a mutation that eliminates the neurotoxic efficacy of PAPP-Cl04 (tyrosine 687) also abolishes its ability to bind to the site identified in this study.
The relationship between binding and pH may be due to a pH-related aggregation of the ligand. The increase in ,f3APP-Cl 04 binding to NGF-treated PC 12 cells at pH 7.7 could result from low-order aggregation of the ligand, which would have little effect on receptor occupancy but would result in the binding of small aggregates of ligand at each site. If the extent of aggregation increases with increased pH, the binding domains of the ligand may become inaccessible, resulting in decreased receptor occupancy. Finally, when the aggregates become large enough, the effect of low receptor occupancy would be offset by the binding of large aggregates of the ligand at each site, resulting in the return of measurable amounts of binding.
It is surprising that the binding site for PAPP-Cl04 does not recognize tachykinins. P/A4 (the amyloid encoding sequence of PAPP) has also been reported to be neurotoxic and to have its toxicity reversed by various tachykinin peptides (Yankner et al., 1990) . Because PIA4 is contained within the ,L?APP-Cl04 domain, it seems reasonable to expect that both peptides would have a similar site of action and therefore would be inhibited by similar agents. The present data do not support this idea. Tachykinins inhibit neither PAPP-Cl04 binding nor its neurotoxicity to NGF-treated PC 12 cells.
Mutational analysis of PAPP-Cl04 neurotoxicity and binding indicates that alteration of a serine in a putative serine protease active site within the P/A4 coding sequence, at the amino terminus of pAPP-C104, does not affect its neurotoxicity. However, alteration of a tyrosine located nine residues from the carboxy terminus of PAPP-C 104 (tyrosine 687) abolishes both the neurotoxicity of the molecule and also its ability to inhibit binding of ?S-PAPP-Cl04 to NGF-treated PC12 cells. This tyrosine is contained within a sequence of amino acids homologous to those surrounding phosphotyrosines in integrins and some growth factor receptors, suggesting that phosphorylation of tyrosine 687 may be a requirement for the binding and neurotoxic activities of PAPP-C 104.
Degeneration of PC12 cells exposed to PAPP-Cl04 is characterized by the appearance of vacuolar inclusions in the cell body, accompanied by retraction of neurites and loss of adherence of cells to the substrate. The cells that remain tend to clump together, and to display fasciculation of processes. Primary rat cortical or hippocampal neurons treated with @APP-ClOkonditioned medium exhibit the same pattern of degeneration (A. Spanoyannis and R. L. Neve, unpublished observations). These characteristics suggest that PAPP-Cl04 may cause cell loss by virtue of its interference with cell-substrate interactions during process outgrowth. Isolation and identification of the cell surface receptor to which PAPP-Cl04 binds will aid us in defining the mechanism by which this molecule causes neurodegeneration.
